Cholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use in Older Adults with End-Stage Dementia: A Survey of Hospice Medical Directors
Authors:
- 1 September 2009
- journal article
- research article
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 12 (9) , 779-783
Abstract
Background: Cholinesterase inhibitors and N-methyl-D-aspartic acid (NMDA) receptor antagonists are Food and Drug Administration (FDA) approved for the treatment of moderate to severe Alzheimer's disease. As dementia progresses to the end stage and patients become hospice-eligible, clinicians consider whether or not to continue these therapies without the benefit of scientific evidence. We sought to describe hospice medical directors practice patterns and experiences in the use and discontinuation of cholinesterase inhibitors and NMDA receptor antagonists in hospice patients that meet the Medicare hospice criteria for dementia. Study Design: Mail survey of hospice medical directors from a random sample from the National Hospice and Palliative Care Organization. Results: Of the 413 eligible participants, 152 completed surveys were returned, yielding a response rate of 37%. Of the respondents, 75% and 33% reported that at least 20% of their patients were taking a cholinesterase inhibitor or memantine, respectively, at the time of hospice admission. The majority of respondents do not consider these therapies effective in persons with end-stage dementia, however, a subset believe that these medications improved patient outcomes including stabilization of cognition (22%), decrease in challenging behaviors (28%), and maintenance of patient function (22%) as well as caregiver outcomes namely reduced caregiver burden (20%) and improved caregiver quality of life (20%). While 80% of respondents recommended discontinuing these therapies to families at the time of hospice enrollment, 72% of respondents reported that families experienced difficulty stopping these therapies. A subset of respondents observed accelerated cognitive (30%) and functional decline (26%) or emergence of challenging behaviors (32%) with medication discontinuation. Conclusions: The findings from this survey indicate that cholinesterase inhibitors and/or NMDA receptor antagonists are prescribed for a subset of patients with advanced dementia and that a proportion of hospice medical directors report clinical benefit from the ongoing use of these agents. In addition, physician preferences for discontinuing these therapies are frequently at odds with the wishes of family members. Prospective studies are needed to evaluate the clinical impact of the discontinuation of these therapies on patient and caregiver outcomes.Keywords
This publication has 13 references indexed in Scilit:
- Acetylcholinesterase Inhibitor and N-Methyl- D -Aspartic Acid Receptor Antagonist Use among Hospice Enrollees with a Primary Diagnosis of DementiaJournal of Palliative Medicine, 2008
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice GuidelineAnnals of Internal Medicine, 2008
- A Population‐Based Study of Cholinesterase Inhibitor Use for DementiaJournal of the American Geriatrics Society, 2007
- Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled studyThe Lancet, 2006
- Donepezil use in US nursing homesAging Clinical and Experimental Research, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology, 2001
- Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer DiseaseArchives of Neurology, 2001
- Donepezil Therapy in Clinical PracticeArchives of Neurology, 2000